Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside
Recent years, particularly the COVID-19 pandemic, can be considered a turning point for pharmacovigilance and pharmacoepidemiology in terms of their role in drug safety and drug utilization monitoring in clinical practice. In this context, researchers operating in the fields of pharmacovigilance and...
Saved in:
| Format: | Online |
|---|---|
| Sprog: | engelsk |
| Udgivet: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Fag: | |
| Online adgang: | ONIX_20240514_9783725806812_401 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
| _version_ | 1863729693018030080 |
|---|---|
| collection | Directory of Open Access Books |
| description | Recent years, particularly the COVID-19 pandemic, can be considered a turning point for pharmacovigilance and pharmacoepidemiology in terms of their role in drug safety and drug utilization monitoring in clinical practice. In this context, researchers operating in the fields of pharmacovigilance and pharmacoepidemiology have extensive knowledge about approved medications, many of which have been or are currently undergoing clinical trials for repurposing. Among them, clinical pharmacologists’ knowledge can be used and translated to optimize dosing and treatment regimens and to assess the relationship between drug exposure and adverse drug events, with the crucial aims of optimizing drugs’ efficacy and ensuring drug safety in a real-world setting. Real-world data are crucial to further establish the safety profile of pharmacological treatments. As a next step, real-world data from electronic health databases may be used in pharmacovigilance and pharmacoepidemiology to monitor drug utilization patterns, as well as the efficacy and safety of drugs in large populations. Furthermore, this approach will be particularly useful for the monitoring of COVID-19 vaccines’ efficacy and safety. In this reprint, experts submited population-based studies (cohort or case–control studies), drug utilization studies, systematic reviews and meta-analyses, and review articles that contribute to improving the understanding of the role of pharmacovigilance and pharmacoepidemiology before, during, and after the COVID-19 pandemic. |
| format | Online |
| id | doab-20.500.12854ir-137805 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1378052024-05-14T14:31:57Z Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside Vannacci, Alfredo Lombardi, Niccolò Crescioli, Giada hypersensitivity drug allergy anaphylaxis emergency department hospitalization pharmacovigilance n/a critical care outcomes patient safety medication therapy management electronic health records drug–drug interactions machine learning neonatal intensive care unit adverse drug reactions empagliflozin safety efficacy Saudi patients type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors metformin major cardiovascular events disproportionality analysis real-world evidence study contrast media spontaneous reporting COVID-19 COVID-19 vaccines mRNA vaccines vaccines with a viral vector immunization safety surveillance praziquantel albendazole school children preventive chemotherapy cohort event monitoring schistosomiasis STH Ethiopia drug safety mRNA-based vaccine multiple sclerosis AEFI observational study COPD Medicare medication adherence COVID-19 pandemic geriatric clinical toxicology intoxication poison control centre clinical practice children hospitalisation decision making risk perception risk/benefit tradeoff COVID-19 vaccination pregnancy breastfeeding maternal vaccination three doses Recent years, particularly the COVID-19 pandemic, can be considered a turning point for pharmacovigilance and pharmacoepidemiology in terms of their role in drug safety and drug utilization monitoring in clinical practice. In this context, researchers operating in the fields of pharmacovigilance and pharmacoepidemiology have extensive knowledge about approved medications, many of which have been or are currently undergoing clinical trials for repurposing. Among them, clinical pharmacologists’ knowledge can be used and translated to optimize dosing and treatment regimens and to assess the relationship between drug exposure and adverse drug events, with the crucial aims of optimizing drugs’ efficacy and ensuring drug safety in a real-world setting. Real-world data are crucial to further establish the safety profile of pharmacological treatments. As a next step, real-world data from electronic health databases may be used in pharmacovigilance and pharmacoepidemiology to monitor drug utilization patterns, as well as the efficacy and safety of drugs in large populations. Furthermore, this approach will be particularly useful for the monitoring of COVID-19 vaccines’ efficacy and safety. In this reprint, experts submited population-based studies (cohort or case–control studies), drug utilization studies, systematic reviews and meta-analyses, and review articles that contribute to improving the understanding of the role of pharmacovigilance and pharmacoepidemiology before, during, and after the COVID-19 pandemic. 2024-05-14T14:31:49Z 2024-05-14T14:31:49Z 2024 book ONIX_20240514_9783725806812_401 9783725806812 9783725806829 https://directory.doabooks.org/handle/20.500.12854/137805 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9040 https://mdpi.com/books/pdfview/book/9040 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0682-9 10.3390/books978-3-7258-0682-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725806812 9783725806829 192 open access |
| spellingShingle | hypersensitivity drug allergy anaphylaxis emergency department hospitalization pharmacovigilance n/a critical care outcomes patient safety medication therapy management electronic health records drug–drug interactions machine learning neonatal intensive care unit adverse drug reactions empagliflozin safety efficacy Saudi patients type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors metformin major cardiovascular events disproportionality analysis real-world evidence study contrast media spontaneous reporting COVID-19 COVID-19 vaccines mRNA vaccines vaccines with a viral vector immunization safety surveillance praziquantel albendazole school children preventive chemotherapy cohort event monitoring schistosomiasis STH Ethiopia drug safety mRNA-based vaccine multiple sclerosis AEFI observational study COPD Medicare medication adherence COVID-19 pandemic geriatric clinical toxicology intoxication poison control centre clinical practice children hospitalisation decision making risk perception risk/benefit tradeoff COVID-19 vaccination pregnancy breastfeeding maternal vaccination three doses Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title | Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title_full | Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title_fullStr | Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title_full_unstemmed | Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title_short | Medication Safety and Pharmacovigilance in Clinical: From the Researcher Bench to the Patient Bedside |
| title_sort | medication safety and pharmacovigilance in clinical from the researcher bench to the patient bedside |
| topic | hypersensitivity drug allergy anaphylaxis emergency department hospitalization pharmacovigilance n/a critical care outcomes patient safety medication therapy management electronic health records drug–drug interactions machine learning neonatal intensive care unit adverse drug reactions empagliflozin safety efficacy Saudi patients type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors metformin major cardiovascular events disproportionality analysis real-world evidence study contrast media spontaneous reporting COVID-19 COVID-19 vaccines mRNA vaccines vaccines with a viral vector immunization safety surveillance praziquantel albendazole school children preventive chemotherapy cohort event monitoring schistosomiasis STH Ethiopia drug safety mRNA-based vaccine multiple sclerosis AEFI observational study COPD Medicare medication adherence COVID-19 pandemic geriatric clinical toxicology intoxication poison control centre clinical practice children hospitalisation decision making risk perception risk/benefit tradeoff COVID-19 vaccination pregnancy breastfeeding maternal vaccination three doses |
| topic_facet | hypersensitivity drug allergy anaphylaxis emergency department hospitalization pharmacovigilance n/a critical care outcomes patient safety medication therapy management electronic health records drug–drug interactions machine learning neonatal intensive care unit adverse drug reactions empagliflozin safety efficacy Saudi patients type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors metformin major cardiovascular events disproportionality analysis real-world evidence study contrast media spontaneous reporting COVID-19 COVID-19 vaccines mRNA vaccines vaccines with a viral vector immunization safety surveillance praziquantel albendazole school children preventive chemotherapy cohort event monitoring schistosomiasis STH Ethiopia drug safety mRNA-based vaccine multiple sclerosis AEFI observational study COPD Medicare medication adherence COVID-19 pandemic geriatric clinical toxicology intoxication poison control centre clinical practice children hospitalisation decision making risk perception risk/benefit tradeoff COVID-19 vaccination pregnancy breastfeeding maternal vaccination three doses |
| url | ONIX_20240514_9783725806812_401 |